Literature DB >> 7633189

Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy.

E Bäckman1, K G Henriksson.   

Abstract

Forty-one boys, aged 4.0-19.4 yr, with Duchenne or Becker muscular dystrophy, took part in a 12-month randomized, double-blind cross-over trial in which the patients received 0.35 mg kg-1 day-1 prednisolone for six months and placebo for six months. One patient stopped the treatment because of excessive weight gain. The boys were assessed every third month with a comprehensive test battery of muscle force and function. The results support earlier reports that prednisolone treatment can either improve muscle force and function or diminish the deterioration of muscle function in both Becker and Duchenne muscular dystrophy.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7633189     DOI： 10.1016/0960-8966(94)00048-e

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


  14 in total

Review 1.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

Review 2.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 3.  Regulatory interactions between muscle and the immune system during muscle regeneration.

Authors:  James G Tidball; S Armando Villalta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-10       Impact factor: 3.619

4.  A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Authors:  Jerry R Mendell; Zarife Sahenk; Vinod Malik; Ana M Gomez; Kevin M Flanigan; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Eric Meadows; Sarah Lewis; Lyndsey Braun; Kim Shontz; Maria Rouhana; Kelly Reed Clark; Xiomara Q Rosales; Samiah Al-Zaidy; Alessandra Govoni; Louise R Rodino-Klapac; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-17       Impact factor: 11.454

Review 5.  Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.

Authors:  Kasia Dzierlega; Toshifumi Yokota
Journal:  Gene Ther       Date:  2020-06-01       Impact factor: 5.250

6.  Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle.

Authors:  David W Hammers; Cora C Hart; Andreas Patsalos; Michael K Matheny; Lillian A Wright; Laszlo Nagy; H Lee Sweeney
Journal:  JCI Insight       Date:  2020-01-16

Review 7.  Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  David Gloss; Richard T Moxley; Stephen Ashwal; Maryam Oskoui
Journal:  Neurology       Date:  2016-02-02       Impact factor: 9.910

Review 8.  Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.

Authors:  Corrado Angelini; Enrico Peterle
Journal:  Acta Myol       Date:  2012-05

9.  Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype.

Authors:  Nanna Witting; Morten Duno; John Vissing
Journal:  Acta Myol       Date:  2011-12

Review 10.  Advancements in stem cells treatment of skeletal muscle wasting.

Authors:  Mirella Meregalli; Andrea Farini; Clementina Sitzia; Yvan Torrente
Journal:  Front Physiol       Date:  2014-02-12       Impact factor: 4.566
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.